Momotaro-Gene Inc.   Report issue

For profit Phase 2
Founded: Okayama Japan (2007)

Organization Overview

First Clinical Trial
2010
NCT01197209
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Consultant Momotaro Gene Inc. | Momotaro-Gene Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

ad-reic/dkk-3 (2 trials)

mtg201 (1 trial)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Mesothelioma (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3